Please select your page
  • Slide
  • Slide
  • Slide

Press release

CERENIS Therapeutics acquires LYPRO Biosciences expanding its HDL strategy
into immuno-oncology and chemotherapeutic drug delivery

8 novembre 2017,

• Combining LYPRO Biosciences’ NanoDisk® technology with CERENIS’ HDL solution to build the first HDL nanoparticle delivery platform to be initially dedicated to the oncology market

• Using its existing technologies with LYPRO’s NanoDisk® discoidal HDL, CERENIS is positioned to utilize HDL related particles to selectively target a wide variety of tissues

• Phase I study, evaluating the safety of the platform technology in active drug delivery to cancer tissues, to be launched by the end of 2019

• New strategic markets and value-creation prospects: Immuno-oncology is one of the most promising cancer treatment technology in a market valued at $100 billion by 2020


 Click here to download the slideshow of the presentation

Full Press Release

Bringing HDL breakthroughs to patients

The HDL company

Cerenis Therapeutics is an international biopharmaceutical company dedicated to the discovery and development of innovative HDL therapies for the treatment of cardiovascular and metabolic diseases. HDL is the primary mediator of the reverse lipid transport, or RLT, the only natural pathway by which excess cholesterol is removed from arteries and is transported to the liver for elimination from the body.

Cerenis is developing a portfolio of HDL therapies, including HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients such as post-ACS patients and patients with HDL deficiency, and drugs which increase HDL for patients with low number of HDL particles to treat atherosclerosis and associated metabolic diseases.

Cerenis is well-positioned to become the leader in the HDL therapeutic market with a broad portfolio of programs in development.

What is HDL deficiency?

HypoAlphalipoproteinemia (“low HDL”), as a general term, has historically been defined clinically as an HDL-cholesterol (HDL-C) less than 40 mg/dL (1.0 mmol/L) in men, and less than 50 mg/dL (1.3 mmol/L) in women. A number of etiologies, often metabolic, can underlie a reduced circulating level of cholesterol in the HDL fraction, for example diabetes, Metabolic Syndrome, obesity, and lack of physical activity (thus called secondary hypoAlphalipoproteinemia). In a very small percentage of the population, particularly among patients with the very lowest HDL-C values, there are patients who have a genetic defect (thus called primary hypoalphalipoproteinemia) affecting either the constituent components of the pre-β particle, the process of pre-β particle synthesis, the steps leading to maturation into an alpha HDL particle, or the rates of catabolism – any of which alone or in combination can then result in an inherited condition of a very low circulating HDL particle number.

Read more

Interview with Professor Jean Ferrières ,
Cardiologist at the CHU Toulouse Rangueil



Cerenis Therapeutics Holding SA
265 rue de la Découverte - Bât. A
31670 Labège, France
Tél. : +33 (0) 5 62 24 97 06
Fax : +33 (0) 5 62 19 04 17


Cerenis Therapeutics Inc
PO Box 861
Lakeland, MI 48143